199 related articles for article (PubMed ID: 30206771)
1. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.
Celik E; Ozkaya HM; Poyraz BC; Saglam T; Kadioglu P
Endocrine; 2018 Dec; 62(3):692-700. PubMed ID: 30206771
[TBL] [Abstract][Full Text] [Related]
2. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas.
Ozkaya HM; Sahin S; Korkmaz OP; Durcan E; Sahin HR; Celik E; Poyraz BC; Kadioglu P
Growth Horm IGF Res; 2020 Dec; 55():101356. PubMed ID: 33010581
[TBL] [Abstract][Full Text] [Related]
3. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.
Dogansen SC; Cikrikcili U; Oruk G; Kutbay NO; Tanrikulu S; Hekimsoy Z; Hadzalic A; Gorar S; Omma T; Mert M; Akbaba G; Yalin GY; Bayram F; Ozkan M; Yarman S
J Clin Endocrinol Metab; 2019 Jul; 104(7):2527-2534. PubMed ID: 30848825
[TBL] [Abstract][Full Text] [Related]
4. Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review.
Hamblin R; Karavitaki N
Arch Med Res; 2023 Dec; 54(8):102910. PubMed ID: 37985276
[TBL] [Abstract][Full Text] [Related]
5. Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas.
Hinojosa-Amaya JM; Johnson N; González-Torres C; Varlamov EV; Yedinak CG; McCartney S; Fleseriu M
Front Endocrinol (Lausanne); 2020; 11():579606. PubMed ID: 33193096
[No Abstract] [Full Text] [Related]
6. Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors.
De Sousa SMC; Baranoff J; Rushworth RL; Butler J; Sorbello J; Vorster J; Thompson T; McCormack AI; Inder WJ; Torpy DJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31580439
[TBL] [Abstract][Full Text] [Related]
7. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study.
Almalki MH; Alsuraikh MA; Almalki E; Aziz F; Almazrouei R; AlDahmani KM; Alshahrani F; Alaqeel M; Mahzari M; Ekhzaimy A
Pituitary; 2024 Apr; 27(2):197-203. PubMed ID: 38345719
[TBL] [Abstract][Full Text] [Related]
8. The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study.
Ke X; Wang L; Chen M; Liu S; Yu N; Duan L; Gong F; Zhu H
BMC Endocr Disord; 2022 Apr; 22(1):97. PubMed ID: 35410236
[TBL] [Abstract][Full Text] [Related]
9. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.
Bancos I; Nannenga MR; Bostwick JM; Silber MH; Erickson D; Nippoldt TB
Clin Endocrinol (Oxf); 2014 Jun; 80(6):863-8. PubMed ID: 24274365
[TBL] [Abstract][Full Text] [Related]
10. Effect of Dopaminergic Therapy on Impulse Control Disorders in Patients With a Prolactinoma.
Ozdeniz Varan E; Gurvit H
Cogn Behav Neurol; 2023 Mar; 36(1):1-8. PubMed ID: 36149404
[TBL] [Abstract][Full Text] [Related]
11. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.
Ioachimescu AG; Fleseriu M; Hoffman AR; Vaughan Iii TB; Katznelson L
Eur J Endocrinol; 2019 Jan; 180(1):31-40. PubMed ID: 30400048
[TBL] [Abstract][Full Text] [Related]
12. Association of dopamine agonist use with impulse control disorders in Parkinson disease.
Weintraub D; Siderowf AD; Potenza MN; Goveas J; Morales KH; Duda JE; Moberg PJ; Stern MB
Arch Neurol; 2006 Jul; 63(7):969-73. PubMed ID: 16831966
[TBL] [Abstract][Full Text] [Related]
13. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study.
Beccuti G; Guaraldi F; Natta G; Cambria V; Prencipe N; Cicolin A; Montanaro E; Lopiano L; Ghigo E; Zibetti M; Grottoli S
J Endocrinol Invest; 2021 Aug; 44(8):1699-1706. PubMed ID: 33314003
[TBL] [Abstract][Full Text] [Related]
14. A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With Prolactinoma.
Sahin S; Sudutan T; Kavla Y; Durcan E; Özogul YY; Poyraz BC; Sayitoglu M; Ozkaya HM; Kadioglu P
J Clin Endocrinol Metab; 2023 May; 108(6):e275-e282. PubMed ID: 36494095
[TBL] [Abstract][Full Text] [Related]
15. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.
Hamidianjahromi A; Tritos NA
Rev Endocr Metab Disord; 2022 Oct; 23(5):1089-1099. PubMed ID: 36125673
[TBL] [Abstract][Full Text] [Related]
16. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma.
Bulwer C; Conn R; Shankar A; Ferrau F; Kapur S; Ederies A; Korbonits M; Spoudeas HA
Clin Endocrinol (Oxf); 2017 Jun; 86(6):862-864. PubMed ID: 28346715
[No Abstract] [Full Text] [Related]
17. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
[TBL] [Abstract][Full Text] [Related]
18. Impulse control disorders in elderly patients.
Tamam L; Bican M; Keskin N
Compr Psychiatry; 2014 May; 55(4):1022-8. PubMed ID: 24405774
[TBL] [Abstract][Full Text] [Related]
19. Treating prolactinomas with dopamine agonists: always worth the gamble?
Noronha S; Stokes V; Karavitaki N; Grossman A
Endocrine; 2016 Feb; 51(2):205-10. PubMed ID: 26336835
[TBL] [Abstract][Full Text] [Related]
20. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma.
Thondam SK; Alusi S; O'Driscoll K; Gilkes CE; Cuthbertson DJ; Daousi C
Clin Neuropharmacol; 2013; 36(5):170-2. PubMed ID: 24045609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]